Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > TNF(Gene name) > Human
  • Add your favorite
  • TNF (Gene name),
  • Tumor necrosis factor (Protein name ),  TNFA_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Citations  (8)
  • |
  • Feedback
  • Gene name:
    TNF(TNFA;TNFSF2);
    Protein name:
    Tumor necrosis factor;
    Alternative:
    Tumor necrosis factor ligand superfamily member 2(TNF-a);Cachectin;TNF-alpha;
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Homotrimer.
    Function:
    Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation.
    Subcellular Location:
    Tumor necrosis factor, soluble form Secreted
    Protein Attributes:
    Sequence length:
    233
    Sequence:
    50:
    MSTESMIRDV | ELAEEALPKK | TGGPQGSRRC | LFLSLFSFLI | VAGATTLFCL | 
    100:
    LHFGVIGPQR | EEFPRDLSLI | SPLAQAVRSS | SRTPSDKPVA | HVVANPQAEG | 
    150:
    QLQWLNRRAN | ALLANGVELR | DNQLVVPSEG | LYLIYSQVLF | KGQGCPSTHV | 
    200:
    LLTHTISRIA | VSYQTKVNLL | SAIKSPCQRE | TPEGAEAKPW | YEPIYLGGVF | 
    233:
    QLEKGDRLSA | EINRPDYLDF | AESGQVYFGI | IAL
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    String:
    Pfam:
    SMR:
    MIM:
    KEGG:
    Uniprot:
     
    FOR
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133d
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    MSDS:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Tumor necrosis factor
    Cat.:
    E0133b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133d
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Tumor necrosis factor
    MSDS:
    Please sign in first.
    CLIA Kit for Human Tumor necrosis factor
    Cat.:
    U0133r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human Tumor necrosis factor
    Cat.:
    P0133Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Tumor necrosis factor
    Polyclonal Antibody for Human Tumor necrosis factor
    Polyclonal Antibody for Human Tumor necrosis factor
    Polyclonal Antibody for Human Tumor necrosis factor
    Cat.:
    P0133Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Tumor necrosis factor
    Polyclonal Antibody for Human Tumor necrosis factor
    Cat.:
    P0133Rb-r
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Monoclonal Antibody for Human Tumor necrosis factor
    Protein for Human Tumor necrosis factor
    Protein for Human Tumor necrosis factor
    Protein for Human Tumor necrosis factor
    Protein for Human Tumor necrosis factor
    Protein for Human Tumor necrosis factor
    Cat.:
    R0133h
    Price:
    Please sign in first.
    Packing:
    1mg
    Purity:
    >90%
    Protein for Human Tumor necrosis factor
    Cat.:
    R0133m
    Price:
    Please sign in first.
    Packing:
    1mg
    Purity:
    >90%
    Protein for Human Tumor necrosis factor
    Cat.:
    R0133r
    Price:
    Please sign in first.
    Packing:
    1mg
    Purity:
    >90%

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤5.2%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.4%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤8.0%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of TNF into serum and plasma .

    Sample Type

    Average(%)

    Recovery  Range (%)

    Serum

    102

    95-114

    Plasma

    96

    93-99

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of TNF into serum and plasma .

    Sample Type

    Average(%)

    Recovery  Range (%)

    Serum

    89

    86-104

    Plasma

    95

    86-105

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of TNF and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    96-101%

    96-105%

    98-104%

    98-107%

    EDTA plasma(n=5)

    95-103%

    97-107%

    100-110%

    88-103%

    heparin plasma(n=5)

    98-103%

     

    96-102%

    93-104%

    95-115%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of TNF and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-103%

    90-101%

    98-109%

    97-110%

    EDTA plasma(n=5)

    101-105%

    97-109%

    89-107%

    99-108%

    heparin plasma(n=5)

    98-107%

     

    96-110%

    100-112%

    101-116%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Citations
    [2].
    Jing Tang, Xi Chen, Weifeng Tu, Yuanbo Guo, Zhenlong Zhao, Qiong Xue, Chunshui Lin, Jinfang Xiao, Xuegang Sun, Tao Tao, Miaoning Gu, Youtan Liu
    [3].
    Yongyan Zhang, Ping Han, Na Wu, Bing He, Yan Lu, Shuwen Li, Yang Liu, Sheng Zhao, Letong Liu and Yan L
    References
    1. 1.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    2. 2.
      "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin."
      Pennica D. , Nedwin G.E. , Hayflick J.S. , Seeburg P.H. , Derynck R. , Palladino M.A. , Kohr W.J. , Aggarwal B.B. , Goeddel D.V.
      Nature312:724-729(1984) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]
    3. 3.
      "Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor."
      Shirai T. , Yamaguchi H. , Ito H. , Todd C.W. , Wallace R.B.
      Nature313:803-806(1985) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]
    4. 4.
      "Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization."
      Nedwin G.E. , Naylor S.L. , Sakaguchi A.Y. , Smith D.H. , Jarrett-Nedwin J. , Pennica D. , Goeddel D.V. , Gray P.W.
      Nucleic Acids Res.13:6361-6373(1985) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]
    5. 5.
      "Molecular cloning of the complementary DNA for human tumor necrosis factor."
      Wang A.M. , Creasey A.A. , Ladner M.B. , Lin L.S. , Strickler J. , van Arsdell J.N. , Yamamoto R. , Mark D.F.
      Science228:149-154(1985) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA]
    6. 6.
      "Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor."
      Marmenout A. , Fransen L. , Tavernier J. , van der Heyden J. , Tizard R. , Kawashima E. , Shaw A. , Johnson M.J. , Semon D. , Mueller R. , Ruysschaert M.-R. , van Vliet A. , Fiers W.
      Eur. J. Biochem.152:515-522(1985) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    7. 7.
      "Dense Alu clustering and a potential new member of the NF kappa B family within a 90 kilobase HLA class III segment."
      Iris F.J.M. , Bougueleret L. , Prieur S. , Caterina D. , Primas G. , Perrot V. , Jurka J. , Rodriguez-Tome P. , Claverie J.-M. , Dausset J. , Cohen D.
      Nat. Genet.3:137-145(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    8. 8.
      "A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC."
      Neville M.J. , Campbell R.D.
      J. Immunol.162:4745-4754(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    9. 9.
      "Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse."
      Xie T. , Rowen L. , Aguado B. , Ahearn M.E. , Madan A. , Qin S. , Campbell R.D. , Hood L.
      Genome Res.13:2621-2636(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    10. 10.
      "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region."
      Shiina S. , Tamiya G. , Oka A. , Inoko H.
      Submitted (1999-09) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    11. 11.
      "Genome diversity in HLA: a new strategy for detection of genetic polymorphisms in expressed genes within the HLA class III and class I regions."
      Shiina T. , Ota M. , Katsuyama Y. , Hashimoto N. , Inoko H.
      Submitted (2002-07) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    12. 12.
      SeattleSNPs variation discovery resource
      Submitted (2001-12) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    13. 13.
      NIEHS SNPs program
      Submitted (2003-01) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANT LEU-84
    14. 14.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
      tissue: Blood.
    15. 15.
      "O-glycosylated species of natural human tumor-necrosis factor-alpha."
      Takakura-Yamamoto R. , Yamamoto S. , Fukuda S. , Kurimoto M.
      Eur. J. Biochem.235:431-437(1996) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 77-99;GLYCOSYLATION AT SER-80
    16. 16.
      Jang J.S. , Kim B.E.
      Submitted (1998-01) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 77-233
    17. 17.
      Shao C. , Yan W. , Zhu F. , Yue W. , Chai Y. , Zhao Z. , Wang C.
      Submitted (2000-03) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 84-214
      tissue: Prostatic carcinoma.
    18. 18.
      "Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells."
      Pocsik E. , Duda E. , Wallach D.
      J. Inflamm.45:152-160(1995) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION (MEMBRANE FORM)
    19. 19.
      "A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'."
      Watts A.D. , Hunt N.H. , Wanigasekara Y. , Bloomfield G. , Wallach D. , Roufogalis B.D. , Chaudhri G.
      EMBO J.18:2119-2126(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION BY CK1;DEPHOSPHORYLATION
    20. 20.
      "Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis."
      Ostade X.V. , Tavernier J. , Prange T. , Fiers W.
      EMBO J.10:827-836(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: MUTAGENESIS
    21. 21.
      "Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues."
      Stevenson F.T. , Bursten S.L. , Locksley R.M. , Lovett D.H.
      J. Exp. Med.176:1053-1062(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: MYRISTOYLATION AT LYS-19 AND LYS-20
    22. 22.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CLEAVAGE BY ADAM17
    23. 23.
      "A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria."
      Knight J.C. , Udalova I. , Hill A.V. , Greenwood B.M. , Peshu N. , Marsh K. , Kwiatkowski D.
      Nat. Genet.22:145-150(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: POLYMORPHISM;INVOLVEMENT IN SUSCEPTIBILITY TO MALARIA
    24. 24.
      "SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production."
      Friedmann E. , Hauben E. , Maylandt K. , Schleeger S. , Vreugde S. , Lichtenthaler S.F. , Kuhn P.H. , Stauffer D. , Rovelli G. , Martoglio B.
      Nat. Cell Biol.8:843-848(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION OF TNF INTRACELLULAR DOMAIN;CLEAVAGE BY SPPL2A AND SPPL2B;SUBCELLULAR LOCATION
    25. 25.
      "A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b."
      Fluhrer R. , Grammer G. , Israel L. , Condron M.M. , Haffner C. , Friedmann E. , Bohland C. , Imhof A. , Martoglio B. , Teplow D.B. , Haass C.
      Nat. Cell Biol.8:894-896(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CLEAVAGE BY SPPL2A AND SPPL2B;CLEAVAGE SITE;INTERACTION WITH SPPL2B;IDENTIFICATION BY MASS SPECTROMETRY
    26. 26.
      "Structure of tumour necrosis factor."
      Jones E.Y. , Stuart D.I. , Walker N.P.
      Nature338:225-228(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS)
    27. 27.
      "The structure of tumour necrosis factor -- implications for biological function."
      Jones E.Y. , Stuart D.I. , Walker N.P.
      J. Cell Sci. Suppl.13:11-18(1990) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS)
    28. 28.
      "The structure of tumor necrosis factor-alpha at 2.6-A resolution. Implications for receptor binding."
      Eck M.J. , Sprang S.R.
      J. Biol. Chem.264:17595-17605(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS)
    29. 29.
      "Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2."
      Reed C. , Fu Z.Q. , Wu J. , Xue Y.N. , Harrison R.W. , Chen M.J. , Weber I.T.
      Protein Eng.10:1101-1107(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF MUTANT ARG-107
    30. 30.
      "High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity."
      Cha S.S. , Kim J.S. , Cho H.S. , Shin N.K. , Jeong W. , Shin H.C. , Kim Y.J. , Hahn J.H. , Oh B.H.
      J. Biol. Chem.273:2153-2160(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF MUTANT SER-3
    31. 31.
      "Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity."
      Balding J. , Kane D. , Livingstone W. , Mynett-Johnson L. , Bresnihan B. , Smith O. , FitzGerald O.
      Arthritis Rheum.48:1408-1413(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INVOLVEMENT IN PSORIATIC ARTHRITIS SUSCEPTIBILITY
    32. 32.
      "Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection."
      Kim Y.J. , Lee H.-S. , Yoon J.-H. , Kim C.Y. , Park M.H. , Kim L.H. , Park B.L. , Shin H.D.
      Hum. Mol. Genet.12:2541-2546(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INVOLVEMENT IN SUSCEPTIBILITY TO HBV INFECTION
    Product Feedback Wall
    Hot Genes
    ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
    Top Searches
    Ubiquitin ELISA Ubiquitin-protein ligase metalloproteinase Asprosin Tumor necrosis TRAP1A vitamin d
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter